First Patient Dosed in the WIN-B Trial of Debio 0123 & Trodelvy® in Advanced Breast Cancer March 3, 2025
Investigator Initiated Ph 2 Trial for Neoadjuvant Muzastotug (ADG126) in CRC Announced February 28, 2025
Go-ahead obtained to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review February 25, 2025
First Patients Enrolled in FORTIFI-HN01, Ph 2/3 Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma February 17, 2025
Ph 3 waveLINE-010 Trial of Zilovertamab Vedotin for the Treatment of 1L DLBCL Patients initiated February 11, 2025
First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 February 11, 2025
Progress and Expansion of Clinical Collaboration Program for ADG126 (muzastotug) + KEYTRUDA combo in MSS CRC announced February 10, 2025
Ongoing Ph 2 trial expanded to optimize stenoparib dose and refine DRP® patient selection criteria February 10, 2025
FIRCE-1 Ph 2 Study of Firi-cel to Discontinue; Advances Remaining Programs While Evaluating Strategic Options February 4, 2025
Ph 1 SB101 Trial expanded to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas January 28, 2025
Global Ph 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for 1L Recurrent Head and Neck Cancer initiated January 28, 2025
Patient Enrollment milestone reached for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM January 28, 2025
Patients Dosed in the First Cohort of the Ph 1/2 SOLARA Trial of BH-30643 for EGFR- and HER2-Mutated NSCLC January 28, 2025
First Patient Dosed in Ph 2 Study of JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable NSCLC January 28, 2025
